Cipla’s manufacturing facility in Goa gets VAI classification
The US FDA conducted a cGMP inspection between June 10-21, 2024
Cipla’s manufacturing facility located in Goa receives a Voluntary Action Indicated (VAI) classification. This decision came after the United States Food and Drug Administration (US FDA) completed a Good Manufacturing Practices (cGMP) inspection conducted between June 10-21, 2024.
- Advertisement -